Search Videos and More
Simmons Cancer Center’s Dr. John Sweetenham to Chair National Comprehensive Cancer Network Board of Directors
John Sweetenham, M.D., Associate Director for Clinical Affairs at UT Southwestern’s Harold C. Simmons Comprehensive Cancer Center, has been elected Chair of the Board of Directors of the National Comprehensive Cancer Network (NCCN).Grant Supports UTSW Push to Make Genomic Data More Accessible
Researchers at UT Southwestern’s Harold C. Simmons Comprehensive Cancer Center are developing an innovative interface to make the wealth of genomics data from next-generation sequencing visible and actionable in real time for clinicians and researchers.DARTBOARD: Novel head & neck cancer trial targets personalized, daily radiation therapy
The DARTBOARD clinical trial will study daily adaptive radiotherapy on head and neck cancers using tumor targeting driven by an AI-driven algorithm developed by UT Southwestern.Working to Reduce Cancer Disparities Across Our Community
The Office of Community Outreach, Engagement, and Equity is committed to maximizing the impact of Simmons research through community engagement in the DFW Metroplex and beyond.Pioneering Initiatives to Modernize Cancer Care
New developments aim to improve clinical outcomes for cancer patients.UT Southwestern Develops Nanotherapeutic to Ward Off Liver Cancer
Physician researchers from UT Southwestern Medical Center have developed an innovative nanotherapeutic drug that prevents cancer from spreading to the liver in mice.Clinical Trial Shows Stereotactic Radiation Extends Systemic Therapy and Slows Kidney Cancer Progression
A new study by the Kidney Cancer Program (KCP) at UT Southwestern’s Harold C. Simmons Comprehensive Cancer Center shows that highly focused radiation to isolated metastases that progress despite drug therapy can prolong drug efficacy in kidney cancer patients, saving the few other drugs for treating kidney cancer for future use.PARP-1 inhibitors can reduce ovarian cancer recurrence risk by 70% in half of patients
UT Southwestern is leading research to find ways to extend the benefits of PARP-1 inhibitor maintenance medication to more patients with more forms of ovarian cancer.Artificial Intelligence Algorithm Developed to Assess Metastatic Potential in Skin Cancers
Using artificial intelligence (AI), researchers from UT Southwestern have developed a way to accurately predict which skin cancers are highly metastatic.The Consequences of Understaging Gastric Cancer
Patients with nonspecific symptoms that overlap with the symptoms of gastric cancers should be evaluated at a center with extensive experience in treating these cancers.Novel Biomarker Might Lead to Personalized, Targeted Therapy
ADP-ribosylation could help scientists predict PARP inhibitor sensitivity in ovarian and breast cancer patients.